Literature DB >> 4921094

The protective effect in bank voles of some strains of BCG.

A Ladefoged, K Bunch-Christensen, J Guld.   

Abstract

The bank vole, like the guinea-pig, can be immunized against tuberculosis with very small doses of BCG, presumably because BCG is sufficiently virulent for both these species to multiply freely until the immunization of the animal has reached a maximum. Large doses of BCG induce an earlier, but not an ultimately stronger, immunity. However, the smallest immunizing dose is not the same for all BCG strains and this is a feature that may be used to differentiate strains. In the studies reported by the authors, the smallest immunizing dose for the bank vole was estimated for 11 BCG strains, some of them widely used in man. The results indicate potency ratios of 20: 1 between the strongest and the weakest strains. The ranking of strains in terms of the smallest immunizing dose was found to be correlated in most, but not in all, cases with a previously reported ranking of the lethal effects of the various strains in golden hamsters. The implications of these findings for production requirements and for reference preparations of BCG are discussed.

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 4921094      PMCID: PMC2427654     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  10 in total

1.  THE ACQUIRED RESISTANCE TO TUBERCULOSIS INDUCED BY BCG VACCINE ASSAYED BY A QUANTITATIVE METHOD ON RED MICE. CLETHRIONOMYS G. GLAREOLUS SCHREB. II. VACCINATION EFFECT OF BCG STRAINS STRONGLY OR MODERATELY VIRULENT FOR HAMSTERS.

Authors:  A JESPERSEN; M W BENTZON
Journal:  Acta Tuberc Pneumol Scand       Date:  1964

2.  The heterogeneity of BCG.

Authors:  S WILLIS; M VANDIVIERE
Journal:  Am Rev Respir Dis       Date:  1961-08

3.  Differential characteristics in vitro and in vivo of several substrains of BCG. IV. Immunizing effectiveness.

Authors:  R J DUBOS; C H PIERCE
Journal:  Am Rev Tuberc       Date:  1956-11

4.  Studies on tuberculin sensitivity and immunity in guinea-pigs induced by vaccination with varying doses of BCG vaccine.

Authors:  A JESPERSEN
Journal:  Acta Pathol Microbiol Scand       Date:  1956

5.  Antituberculous immunity induced in red mice (Clethrionomys G. glareolus Schreb.) by vaccination with living BCG.

Authors:  A JESPERSEN
Journal:  Acta Pathol Microbiol Scand       Date:  1954

6.  The virulence of some strains of BCG for golden hamsters. Further studies.

Authors:  K Bunch-Christensen; A Ladefoged; J Guld
Journal:  Bull World Health Organ       Date:  1970       Impact factor: 9.408

7.  Tuberculosis studies in Muscogee County, Georgia. VII. A twenty-year evaluation of BCG vaccination in a school population.

Authors:  G W Comstock; R G Webster
Journal:  Am Rev Respir Dis       Date:  1969-12

8.  Long-term results of BCG vaccination in the southern United States.

Authors:  G W Comstock; C E Palmer
Journal:  Am Rev Respir Dis       Date:  1966-02

9.  The virulence of some strains of BCG for golden hamsters.

Authors:  K Bunch-Christensen; A Ladefoged; J Guld
Journal:  Bull World Health Organ       Date:  1968       Impact factor: 9.408

10.  Antituberculous immunity induced in mice by vaccination with living cultures of attenuated tubercle bacilli.

Authors:  R J DUBOS; C H PIERCE; W B SCHAEFER
Journal:  J Exp Med       Date:  1953-02-01       Impact factor: 14.307

  10 in total
  11 in total

1.  Quality control of BCG vaccine by WHO: a review of factors that may influence vaccine effectiveness and safety.

Authors:  J B Milstien; J J Gibson
Journal:  Bull World Health Organ       Date:  1990       Impact factor: 9.408

2.  Quantitative evaluation of the effectiveness of Connaught freeze-dried BCG vaccine in mice and in guineapigs.

Authors:  C O Siebenmann; C Barbara
Journal:  Bull World Health Organ       Date:  1974       Impact factor: 9.408

3.  Drug resistance in the Swedish/Norwegian BCG strain.

Authors:  I Hesselberg
Journal:  Bull World Health Organ       Date:  1972       Impact factor: 9.408

4.  Preservation of mycobacteria: 100 percent viability of suspensions stored at -70 C.

Authors:  T H Kim; G P Kubica
Journal:  Appl Microbiol       Date:  1973-06

5.  Resistance of high and low antibody responder lines of mice to the growth of avirulent (BCG) and virulent (H37Rv) strains of mycobacteria.

Authors:  M Gheorghiu; D Mouton; H Lecoeur; M Lagranderie; J C Mevel; G Biozzi
Journal:  Clin Exp Immunol       Date:  1985-01       Impact factor: 4.330

6.  Serial subcultivation of Czechoslovakian and Japanese BCG strains.

Authors:  T W Osborn
Journal:  J Hyg (Lond)       Date:  1980-10

7.  The patterns of in vitro cell-death and inflammatory cytokines induced by distinct BCG vaccine strains are differentially induced in human mononuclear cells.

Authors:  C Ponte; M Hacker; M Moraes; L Castello-Branco; F Silva; P Antas
Journal:  Hum Vaccin Immunother       Date:  2017-11-27       Impact factor: 3.452

8.  Commonly administered BCG strains including an evolutionarily early strain and evolutionarily late strains of disparate genealogy induce comparable protective immunity against tuberculosis.

Authors:  Marcus A Horwitz; Günter Harth; Barbara Jane Dillon; Sasa Maslesa-Galić
Journal:  Vaccine       Date:  2008-11-11       Impact factor: 3.641

9.  A Modified Bacillus Calmette-Guérin (BCG) Vaccine with Reduced Activity of Antioxidants and Glutamine Synthetase Exhibits Enhanced Protection of Mice despite Diminished in Vivo Persistence.

Authors:  Carolyn M Shoen; Michelle S DeStefano; Cynthia C Hager; Kyi-Toe Tham; Miriam Braunstein; Alexandria D Allen; Hiriam O Gates; Michael H Cynamon; Douglas S Kernodle
Journal:  Vaccines (Basel)       Date:  2013-01-11

10.  Reducing the activity and secretion of microbial antioxidants enhances the immunogenicity of BCG.

Authors:  Shanmugalakshmi Sadagopal; Miriam Braunstein; Cynthia C Hager; Jie Wei; Alexandria K Daniel; Markian R Bochan; Ian Crozier; Nathaniel E Smith; Hiriam O Gates; Louise Barnett; Luc Van Kaer; James O Price; Timothy S Blackwell; Spyros A Kalams; Douglas S Kernodle
Journal:  PLoS One       Date:  2009-05-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.